+1 877 302 8632
+1 888 205 9894 (Toll-free)

Fc Receptor (FcRn) antibody

Reactivity: Human cELISA, ELISA, FACS, IF, Func Host: Mouse Monoclonal ADM31 unconjugated
Catalog No. ABIN1774762
  • Target
    Fc Receptor (FcRn)
    • 1
    • 1
    • 1
    • 1
    • 1
    Cell-ELISA (cELISA), ELISA, Flow Cytometry (FACS), Immunofluorescence (IF), Functional Studies (Func)
    based on recognition of the complete native protein expressed on transfected mammalian cells
    Purified, Protein A
    Antibodies were generated by immunizing mouse FcRn-deficient mice with spleen cells from mice transgenic for human FcRn.
    Product Specific Information

    What can the FcRn antibody ABIN1774762 / ADM31 antibody be used for? This monoclonal mouse anti-FcRn antibody is unconjugated and is suitable for the detection of FcRn (Fc receptor) in human samples. The FcRn antibody is validated for Cell ELISA, ELISA, FACS and IF.

    What validation data is available for this FcRn antibody / ADM31 antibody? 6 images for FACS and other applications are available. The product is cited in 15 PubMed publications. User our high quality product to reliably detect Fc receptor.

    The MHC class I-like Fc receptor (FcRn) functions as an intracellular trafficking receptor, uniquely accountable for prolonging the serum half-life of IgG subclass antibodies and facilitating their passage across cellular barriers. Through these actions, FcRn significantly impacts various aspects of antibody biology and pathobiology. Its crucial role in regulating IgG pharmacokinetics has been exploited in the development of therapeutic antibodies and related biological treatments. Additionally, FcRn is involved in the transport of serum albumin, contributing to the improved pharmacokinetic characteristics of albumin-conjugated therapies. However, a lack of dependable serological tools targeting human FcRn has limited the comprehension of its functions and potential therapeutic uses.

  • Application Notes
    • Flow cytometry: 1.2 μg/10^6 cells
    • ELISA: 1:200 - 1:400
    • CELISA: 1:200 - 1:400
    For each application a titration should be performed to determine the optimal concentration.
    For Research Use only
  • Buffer
    phosphate buffered saline, pH 7.2
    Handling Advice
    avoid repeated freezing and thawing
    4 °C
  • Gjølberg, Frick, Mester, Foss, Grevys, Høydahl, Jørstad, Schlothauer, Sandlie, Moe, Andersen: "Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life." in: Communications biology, Vol. 5, Issue 1, pp. 832, (2022) (PubMed).

    Cines, Zaitsev, Rauova, Rux, Stepanova, Krishnaswamy, Sarkar, Kowalska, Zhao, Mast, Blumberg, McCrae, Poncz, Hubbard, Pyzik, Blumberg: "FcRn augments induction of tissue factor activity by IgG-containing immune complexes." in: Blood, Vol. 135, Issue 23, pp. 2085-2093, (2021) (PubMed).

    Hubbard, Pyzik, Rath, Kozicky, Sand, Gandhi, Grevys, Foss, Menzies, Glickman, Fiebiger, Roopenian, Sandlie, Andersen, Sly, Baker, Blumberg: "FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity." in: The Journal of experimental medicine, Vol. 217, Issue 10, (2021) (PubMed).

    Bern, Nilsen, Ferrarese, Sand, Gjølberg, Lode, Davidson, Camire, Bækkevold, Foss, Grevys, Dalhus, Wilson, Høydahl, Christianson, Roopenian, Schlothauer, Michaelsen, Moe, Lombardi, Pinotti, Sandlie et al.: "An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. ..." in: Science translational medicine, Vol. 12, Issue 565, (2021) (PubMed).

    Casulleras, Flores-Costa, Duran-Güell, Alcaraz-Quiles, Sanz, Titos, López-Vicario, Fernández, Horrillo, Costa, de la Grange, Moreau, Arroyo, Clària: "Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis." in: Science translational medicine, Vol. 12, Issue 566, (2021) (PubMed).

    Blumberg, Humphries, Jones, Pearce, Holgate, Hearn, Cheung, Mahmood, Del Tito, Graydon, Stolz, Bitonti, Purohit, de Graaf, Kacena, Andersen, Christianson, Roopenian, Hubbard, Gandhi, Lasseter, Pyzik et al.: "Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. ..." in: Science advances, Vol. 5, Issue 12, pp. eaax9586, (2020) (PubMed).

    Chung, Nguyen, Lin, Lafrance-Vanasse, Scales, Lin, Deng, Williams, Sperinde, Li, Zheng, Sukumaran, Tesar, Ernst, Fischer, Lazar, Prabhu, Song: "An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans." in: mAbs, Vol. 11, Issue 5, pp. 942-955, (2019) (PubMed).

    Swiercz, Mo, Khare, Schneider, Ober, Ward: "Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption." in: Oncotarget, Vol. 8, Issue 2, pp. 3528-3541, (2018) (PubMed).

    Pyzik, Rath, Kuo, Win, Baker, Hubbard, Grenha, Gandhi, Krämer, Mezo, Taylor, McDonnell, Nienaber, Andersen, Mizoguchi, Blumberg, Purohit, Jones, Christianson, Lencer, Sandlie, Kaplowitz, Roopenian et al.: "Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. ..." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, Issue 14, pp. E2862-E2871, (2018) (PubMed).

    Grevys, Nilsen, Sand, Daba, Øynebråten, Bern, McAdam, Foss, Schlothauer, Michaelsen, Christianson, Roopenian, Blumberg, Sandlie, Andersen: "A human endothelial cell-based recycling assay for screening of FcRn targeted molecules." in: Nature communications, Vol. 9, Issue 1, pp. 621, (2018) (PubMed).

    Roopenian, Christianson, Proetzel, Sproule: "Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies." in: Methods in molecular biology (Clifton, N.J.), Vol. 1438, pp. 103-14, (2017) (PubMed).

    Foss, Grevys, Sand, Bern, Blundell, Michaelsen, Pleass, Sandlie, Andersen: "Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization." in: Journal of controlled release : official journal of the Controlled Release Society, Vol. 223, pp. 42-52, (2016) (PubMed).

    Christianson, Sun, Akilesh, Pesavento, Proetzel, Roopenian: "Monoclonal antibodies directed against human FcRn and their applications." in: mAbs, Vol. 4, Issue 2, pp. 208-16, (2014) (PubMed).

    Powner, McKenzie, Christianson, Roopenian, Fruttiger: "Expression of neonatal Fc receptor in the eye." in: Investigative ophthalmology & visual science, Vol. 55, Issue 3, pp. 1607-15, (2014) (PubMed).

    Sand, Dalhus, Christianson, Bern, Foss, Cameron, Sleep, Bjørås, Roopenian, Sandlie, Andersen: "Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies." in: The Journal of biological chemistry, Vol. 289, Issue 24, pp. 17228-39, (2014) (PubMed).

  • Target
    Fc Receptor (FcRn)
    The MHC class I-like Fc receptor (FcRn) is an intracellular trafficking Fc receptor that is uniquely responsible for the extended serum half-life of antibodies of the IgG subclass and their ability to transport across cellular barriers. By performing these functions, FcRn affects numerous facets of antibody biology and pathobiology. Its critical role in controlling IgG pharmacokinetics has been leveraged for the design of therapeutic antibodies and related biologics. FcRn also traffics serum albumin and is responsible for the enhanced pharmacokinetic properties of albumin-conjugated therapeutics.
    Synonyms: IgG receptor FcRn large subunit p51, Neonatal Fc receptor, FCGRT
You are here: